Clinical trial
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of…
NCT04093362 · Taiho Oncology, Inc., Industry · Terminated
Key facts
| NCT number | NCT04093362 |
|---|---|
| Title | Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements |
| Official title | A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3 |
| Acronym | FOENIX-CCA3 |
| Lead sponsor | Taiho Oncology, Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements |
| Intervention type | Drug |
| Interventions | Futibatinib, Cisplatin, Gemcitabine |
| Enrollment | 10 |
| Start date | Jan 6, 2021 |
| Primary completion | Apr 22, 2024 |
| Completion | Apr 22, 2024 |
| First posted | Sep 18, 2019 |
| Last update posted | Feb 7, 2025 |
| Countries | Argentina, Australia, Belgium, Brazil, France, Germany, Hong Kong, Italy, Japan, Mexico, Netherlands, Peru and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: